US 11,874,284 B2
Delta-2-tubulin as a biomarker and therapeutic target for peripheral neuropathy
Francesca Bartolini, New York, NY (US); Maria Elena Pero, New York, NY (US); and Guido Cavaletti, Monza (IT)
Assigned to THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, New York, NY (US); and UNIVERSITÀ DEGLI STUDI DI MILANO-BICOCCA, Milan (IT)
Filed by THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, New York, NY (US); and UNIVERSITÀ DEGLI STUDI DI MILANO-BICOCCA, Milan (IT)
Filed on May 27, 2020, as Appl. No. 16/884,768.
Application 16/884,768 is a continuation of application No. PCT/US2018/063129, filed on Nov. 29, 2018.
Claims priority of provisional application 62/650,133, filed on Mar. 29, 2018.
Claims priority of provisional application 62/592,247, filed on Nov. 29, 2017.
Prior Publication US 2020/0333359 A1, Oct. 22, 2020
Int. Cl. G01N 33/68 (2006.01); A61P 25/02 (2006.01); A61K 45/06 (2006.01); G01N 33/574 (2006.01); A61K 31/7105 (2006.01); A61K 31/69 (2006.01)
CPC G01N 33/6896 (2013.01) [A61K 31/69 (2013.01); A61K 31/7105 (2013.01); A61K 45/06 (2013.01); A61P 25/02 (2018.01); G01N 33/574 (2013.01); G01N 2800/2842 (2013.01); G01N 2800/52 (2013.01)] 3 Claims
 
1. A method for the treatment of chemotherapy-induced peripheral neuropathy in a subject having a cancer, comprising:
a) obtaining a first sample from the subject before treatment with an anti-cancer agent;
b) obtaining a second sample from the subject after treatment with the anti-cancer agent;
c) determining the expression level of a delta-2-tubulin in the second sample is increased compared to the expression level in the first sample; and
d) administering an siRNA or shRNA targeting cytosolic carboxypeptidase 1 (CCP1), wherein the first sample and the second sample comprise a sample of nervous tissue.